@article{df3260c9d6a04746aef2d919701ff335,
title = "Does cilengitide deserve another chance?-Authors' reply",
author = "Roger Stupp and Martin Picard and Michael Weller",
note = "Funding Information: RS declares expenses in relationship with the study from Merck KGaA and has served on advisory boards for Roche, MSD/Merck & Co, and Novartis. MP is employed by Merck KGaA. MW declares consultant or advisory roles for Isarna, Merck Serono, Roche, and Magforce, personal fees from Merck Serono, Roche, MSD, and Magforce, and research funding from Bayer, Merck Serono, Roche, MSD, and Isarna. Copyright: Copyright 2016 Elsevier B.V., All rights reserved.",
year = "2014",
doi = "10.1016/S1470-2045(14)71121-0",
language = "English (US)",
volume = "15",
pages = "e585--e586",
journal = "The Lancet Oncology",
issn = "1470-2045",
publisher = "Lancet Publishing Group",
number = "13",
}